专利名称：TREATMENT OF CANCERS AND
HEMATOPOIETIC STEM CELL DISORDERSPRIVILEGED BY CXCL12-CXCR4INTERACTION
发明人：Stephen Marcus申请号：US15044740申请日：20160216
公开号：US20160235779A1公开日：20160818
摘要：Methods are presented for treating cancers and hematopoietic stem celldisorders, comprising administering to a subject with a cancer or hematopoietic stem celldisorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting,reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4,wherein the cancer or hematopoietic stem cell disorder is one in which interaction ofCXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic
intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
申请人：Cantex Pharmaceuticals, Inc.
地址：Weston FL US
国籍：US
更多信息请下载全文后查看
因篇幅问题不能全部显示，请点此查看更多更全内容